nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP3A4—Thiotepa—urinary bladder cancer	0.0404	0.215	CbGbCtD
Triazolam—CYP2C8—Fluorouracil—urinary bladder cancer	0.0324	0.172	CbGbCtD
Triazolam—CYP3A5—Etoposide—urinary bladder cancer	0.0281	0.149	CbGbCtD
Triazolam—CYP2C8—Etoposide—urinary bladder cancer	0.027	0.144	CbGbCtD
Triazolam—CYP2C9—Fluorouracil—urinary bladder cancer	0.0226	0.12	CbGbCtD
Triazolam—CYP2C9—Cisplatin—urinary bladder cancer	0.0192	0.102	CbGbCtD
Triazolam—CYP3A4—Etoposide—urinary bladder cancer	0.011	0.0583	CbGbCtD
Triazolam—Midazolam—CYP4B1—urinary bladder cancer	0.00879	0.389	CrCbGaD
Triazolam—CYP3A4—Doxorubicin—urinary bladder cancer	0.00748	0.0397	CbGbCtD
Triazolam—CYP2C9—urine—urinary bladder cancer	0.00694	0.0705	CbGeAlD
Triazolam—GABRP—prostate gland—urinary bladder cancer	0.00574	0.0583	CbGeAlD
Triazolam—Clonazepam—NAT2—urinary bladder cancer	0.00544	0.241	CrCbGaD
Triazolam—CYP3A4—urine—urinary bladder cancer	0.00529	0.0538	CbGeAlD
Triazolam—Flunitrazepam—UGT2B7—urinary bladder cancer	0.0047	0.208	CrCbGaD
Triazolam—GABRE—prostate gland—urinary bladder cancer	0.00438	0.0445	CbGeAlD
Triazolam—TSPO—prostate gland—urinary bladder cancer	0.00409	0.0415	CbGeAlD
Triazolam—GABRP—urethra—urinary bladder cancer	0.00384	0.039	CbGeAlD
Triazolam—GABRB3—prostate gland—urinary bladder cancer	0.00371	0.0377	CbGeAlD
Triazolam—GABRE—seminal vesicle—urinary bladder cancer	0.0037	0.0376	CbGeAlD
Triazolam—Oxazepam—UGT2B7—urinary bladder cancer	0.00365	0.162	CrCbGaD
Triazolam—TSPO—seminal vesicle—urinary bladder cancer	0.00346	0.0351	CbGeAlD
Triazolam—GABRB1—vagina—urinary bladder cancer	0.00316	0.0321	CbGeAlD
Triazolam—GABRP—female reproductive system—urinary bladder cancer	0.00313	0.0318	CbGeAlD
Triazolam—TSPO—epithelium—urinary bladder cancer	0.003	0.0305	CbGeAlD
Triazolam—GABRE—urethra—urinary bladder cancer	0.00293	0.0298	CbGeAlD
Triazolam—TSPO—smooth muscle tissue—urinary bladder cancer	0.0029	0.0294	CbGeAlD
Triazolam—GABRP—vagina—urinary bladder cancer	0.00283	0.0288	CbGeAlD
Triazolam—TSPO—renal system—urinary bladder cancer	0.00279	0.0283	CbGeAlD
Triazolam—TSPO—urethra—urinary bladder cancer	0.00274	0.0278	CbGeAlD
Triazolam—GABRR2—lymph node—urinary bladder cancer	0.00262	0.0266	CbGeAlD
Triazolam—CYP3A5—prostate gland—urinary bladder cancer	0.00253	0.0257	CbGeAlD
Triazolam—GABRE—female reproductive system—urinary bladder cancer	0.00239	0.0243	CbGeAlD
Triazolam—TSPO—female reproductive system—urinary bladder cancer	0.00223	0.0227	CbGeAlD
Triazolam—GABRA2—vagina—urinary bladder cancer	0.00218	0.0222	CbGeAlD
Triazolam—GABRE—vagina—urinary bladder cancer	0.00216	0.022	CbGeAlD
Triazolam—GABRB3—female reproductive system—urinary bladder cancer	0.00203	0.0206	CbGeAlD
Triazolam—TSPO—vagina—urinary bladder cancer	0.00202	0.0205	CbGeAlD
Triazolam—CYP2C8—renal system—urinary bladder cancer	0.00191	0.0194	CbGeAlD
Triazolam—CYP3A5—renal system—urinary bladder cancer	0.00173	0.0175	CbGeAlD
Triazolam—CYP2C8—female reproductive system—urinary bladder cancer	0.00153	0.0156	CbGeAlD
Triazolam—GABRA2—lymph node—urinary bladder cancer	0.00141	0.0143	CbGeAlD
Triazolam—GABRE—lymph node—urinary bladder cancer	0.0014	0.0142	CbGeAlD
Triazolam—CYP2C8—vagina—urinary bladder cancer	0.00139	0.0141	CbGeAlD
Triazolam—Discomfort—Gemcitabine—urinary bladder cancer	0.00138	0.00233	CcSEcCtD
Triazolam—Malaise—Cisplatin—urinary bladder cancer	0.00138	0.00233	CcSEcCtD
Triazolam—Chest pain—Fluorouracil—urinary bladder cancer	0.00137	0.00232	CcSEcCtD
Triazolam—Fatigue—Thiotepa—urinary bladder cancer	0.00137	0.00231	CcSEcCtD
Triazolam—Dysgeusia—Etoposide—urinary bladder cancer	0.00137	0.00231	CcSEcCtD
Triazolam—CYP2C9—female reproductive system—urinary bladder cancer	0.00136	0.0138	CbGeAlD
Triazolam—Pain—Thiotepa—urinary bladder cancer	0.00136	0.0023	CcSEcCtD
Triazolam—Constipation—Thiotepa—urinary bladder cancer	0.00136	0.0023	CcSEcCtD
Triazolam—Discomfort—Fluorouracil—urinary bladder cancer	0.00135	0.00229	CcSEcCtD
Triazolam—Muscle spasms—Etoposide—urinary bladder cancer	0.00134	0.00227	CcSEcCtD
Triazolam—Hepatic failure—Doxorubicin—urinary bladder cancer	0.00134	0.00226	CcSEcCtD
Triazolam—Oedema—Gemcitabine—urinary bladder cancer	0.00134	0.00226	CcSEcCtD
Triazolam—Irritability—Methotrexate—urinary bladder cancer	0.00133	0.00224	CcSEcCtD
Triazolam—Confusional state—Fluorouracil—urinary bladder cancer	0.00132	0.00224	CcSEcCtD
Triazolam—Mood swings—Methotrexate—urinary bladder cancer	0.00132	0.00223	CcSEcCtD
Triazolam—Oedema—Fluorouracil—urinary bladder cancer	0.00131	0.00222	CcSEcCtD
Triazolam—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00131	0.00221	CcSEcCtD
Triazolam—Ataxia—Methotrexate—urinary bladder cancer	0.00131	0.00221	CcSEcCtD
Triazolam—TSPO—lymph node—urinary bladder cancer	0.00131	0.0133	CbGeAlD
Triazolam—Osteoarthritis—Epirubicin—urinary bladder cancer	0.0013	0.0022	CcSEcCtD
Triazolam—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.0013	0.0022	CcSEcCtD
Triazolam—Ill-defined disorder—Etoposide—urinary bladder cancer	0.0013	0.00219	CcSEcCtD
Triazolam—CYP3A4—renal system—urinary bladder cancer	0.0013	0.0132	CbGeAlD
Triazolam—Anxiety—Cisplatin—urinary bladder cancer	0.00129	0.00219	CcSEcCtD
Triazolam—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00129	0.00218	CcSEcCtD
Triazolam—Discomfort—Cisplatin—urinary bladder cancer	0.00128	0.00217	CcSEcCtD
Triazolam—Tachycardia—Fluorouracil—urinary bladder cancer	0.00128	0.00217	CcSEcCtD
Triazolam—Affect lability—Epirubicin—urinary bladder cancer	0.00128	0.00216	CcSEcCtD
Triazolam—Anorexia—Gemcitabine—urinary bladder cancer	0.00127	0.00215	CcSEcCtD
Triazolam—Malaise—Etoposide—urinary bladder cancer	0.00126	0.00213	CcSEcCtD
Triazolam—Abdominal pain—Thiotepa—urinary bladder cancer	0.00126	0.00212	CcSEcCtD
Triazolam—Anorexia—Fluorouracil—urinary bladder cancer	0.00125	0.00212	CcSEcCtD
Triazolam—CYP3A5—vagina—urinary bladder cancer	0.00125	0.0127	CbGeAlD
Triazolam—Oedema—Cisplatin—urinary bladder cancer	0.00125	0.00211	CcSEcCtD
Triazolam—Mood swings—Epirubicin—urinary bladder cancer	0.00123	0.00208	CcSEcCtD
Triazolam—Loss of consciousness—Etoposide—urinary bladder cancer	0.00123	0.00208	CcSEcCtD
Triazolam—Ataxia—Epirubicin—urinary bladder cancer	0.00122	0.00207	CcSEcCtD
Triazolam—Tachycardia—Cisplatin—urinary bladder cancer	0.00122	0.00205	CcSEcCtD
Triazolam—Insomnia—Gemcitabine—urinary bladder cancer	0.00121	0.00204	CcSEcCtD
Triazolam—Hypertension—Etoposide—urinary bladder cancer	0.00121	0.00204	CcSEcCtD
Triazolam—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.0012	0.00204	CcSEcCtD
Triazolam—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.0012	0.00204	CcSEcCtD
Triazolam—Paraesthesia—Gemcitabine—urinary bladder cancer	0.0012	0.00203	CcSEcCtD
Triazolam—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00119	0.00201	CcSEcCtD
Triazolam—Chest pain—Etoposide—urinary bladder cancer	0.00119	0.00201	CcSEcCtD
Triazolam—Insomnia—Fluorouracil—urinary bladder cancer	0.00119	0.00201	CcSEcCtD
Triazolam—Somnolence—Gemcitabine—urinary bladder cancer	0.00119	0.00201	CcSEcCtD
Triazolam—Anorexia—Cisplatin—urinary bladder cancer	0.00119	0.00201	CcSEcCtD
Triazolam—Affect lability—Doxorubicin—urinary bladder cancer	0.00118	0.002	CcSEcCtD
Triazolam—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00118	0.00199	CcSEcCtD
Triazolam—Discomfort—Etoposide—urinary bladder cancer	0.00118	0.00199	CcSEcCtD
Triazolam—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00117	0.00198	CcSEcCtD
Triazolam—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00117	0.00198	CcSEcCtD
Triazolam—Somnolence—Fluorouracil—urinary bladder cancer	0.00117	0.00197	CcSEcCtD
Triazolam—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00116	0.00196	CcSEcCtD
Triazolam—Fatigue—Gemcitabine—urinary bladder cancer	0.00115	0.00195	CcSEcCtD
Triazolam—Confusional state—Etoposide—urinary bladder cancer	0.00115	0.00194	CcSEcCtD
Triazolam—Muscular weakness—Epirubicin—urinary bladder cancer	0.00115	0.00194	CcSEcCtD
Triazolam—Pain—Gemcitabine—urinary bladder cancer	0.00114	0.00193	CcSEcCtD
Triazolam—Constipation—Gemcitabine—urinary bladder cancer	0.00114	0.00193	CcSEcCtD
Triazolam—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00114	0.00193	CcSEcCtD
Triazolam—Mood swings—Doxorubicin—urinary bladder cancer	0.00114	0.00193	CcSEcCtD
Triazolam—Asthenia—Thiotepa—urinary bladder cancer	0.00114	0.00193	CcSEcCtD
Triazolam—Ataxia—Doxorubicin—urinary bladder cancer	0.00113	0.00191	CcSEcCtD
Triazolam—Dysuria—Methotrexate—urinary bladder cancer	0.00112	0.0019	CcSEcCtD
Triazolam—Pruritus—Thiotepa—urinary bladder cancer	0.00112	0.0019	CcSEcCtD
Triazolam—Pain—Fluorouracil—urinary bladder cancer	0.00112	0.0019	CcSEcCtD
Triazolam—Paraesthesia—Cisplatin—urinary bladder cancer	0.00112	0.00189	CcSEcCtD
Triazolam—Tachycardia—Etoposide—urinary bladder cancer	0.00111	0.00188	CcSEcCtD
Triazolam—Dyspnoea—Cisplatin—urinary bladder cancer	0.00111	0.00188	CcSEcCtD
Triazolam—Hyperhidrosis—Etoposide—urinary bladder cancer	0.0011	0.00186	CcSEcCtD
Triazolam—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.0011	0.00186	CcSEcCtD
Triazolam—Anorexia—Etoposide—urinary bladder cancer	0.00109	0.00184	CcSEcCtD
Triazolam—Diarrhoea—Thiotepa—urinary bladder cancer	0.00109	0.00184	CcSEcCtD
Triazolam—Decreased appetite—Cisplatin—urinary bladder cancer	0.00108	0.00183	CcSEcCtD
Triazolam—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00108	0.00183	CcSEcCtD
Triazolam—Drowsiness—Methotrexate—urinary bladder cancer	0.00107	0.00181	CcSEcCtD
Triazolam—Pain—Cisplatin—urinary bladder cancer	0.00106	0.0018	CcSEcCtD
Triazolam—Muscular weakness—Doxorubicin—urinary bladder cancer	0.00106	0.00179	CcSEcCtD
Triazolam—Dysuria—Epirubicin—urinary bladder cancer	0.00105	0.00178	CcSEcCtD
Triazolam—Dizziness—Thiotepa—urinary bladder cancer	0.00105	0.00178	CcSEcCtD
Triazolam—Stomatitis—Methotrexate—urinary bladder cancer	0.00104	0.00177	CcSEcCtD
Triazolam—CYP3A4—female reproductive system—urinary bladder cancer	0.00104	0.0105	CbGeAlD
Triazolam—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00103	0.00173	CcSEcCtD
Triazolam—Paraesthesia—Etoposide—urinary bladder cancer	0.00102	0.00173	CcSEcCtD
Triazolam—Dyspnoea—Etoposide—urinary bladder cancer	0.00102	0.00172	CcSEcCtD
Triazolam—Somnolence—Etoposide—urinary bladder cancer	0.00101	0.00171	CcSEcCtD
Triazolam—Vomiting—Thiotepa—urinary bladder cancer	0.00101	0.00171	CcSEcCtD
Triazolam—Drowsiness—Epirubicin—urinary bladder cancer	0.001	0.0017	CcSEcCtD
Triazolam—Dermatitis—Thiotepa—urinary bladder cancer	0.001	0.00169	CcSEcCtD
Triazolam—Headache—Thiotepa—urinary bladder cancer	0.000995	0.00168	CcSEcCtD
Triazolam—Decreased appetite—Etoposide—urinary bladder cancer	0.000992	0.00168	CcSEcCtD
Triazolam—Fatigue—Etoposide—urinary bladder cancer	0.000983	0.00166	CcSEcCtD
Triazolam—Stomatitis—Epirubicin—urinary bladder cancer	0.000977	0.00165	CcSEcCtD
Triazolam—Jaundice—Epirubicin—urinary bladder cancer	0.000977	0.00165	CcSEcCtD
Triazolam—Pain—Etoposide—urinary bladder cancer	0.000976	0.00165	CcSEcCtD
Triazolam—Constipation—Etoposide—urinary bladder cancer	0.000976	0.00165	CcSEcCtD
Triazolam—Dysuria—Doxorubicin—urinary bladder cancer	0.000973	0.00164	CcSEcCtD
Triazolam—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000968	0.00164	CcSEcCtD
Triazolam—Asthenia—Gemcitabine—urinary bladder cancer	0.000958	0.00162	CcSEcCtD
Triazolam—Pruritus—Gemcitabine—urinary bladder cancer	0.000945	0.0016	CcSEcCtD
Triazolam—Nausea—Thiotepa—urinary bladder cancer	0.000943	0.00159	CcSEcCtD
Triazolam—Feeling abnormal—Etoposide—urinary bladder cancer	0.00094	0.00159	CcSEcCtD
Triazolam—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000933	0.00158	CcSEcCtD
Triazolam—Pruritus—Fluorouracil—urinary bladder cancer	0.000929	0.00157	CcSEcCtD
Triazolam—Drowsiness—Doxorubicin—urinary bladder cancer	0.000928	0.00157	CcSEcCtD
Triazolam—Visual impairment—Methotrexate—urinary bladder cancer	0.000927	0.00157	CcSEcCtD
Triazolam—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000917	0.00155	CcSEcCtD
Triazolam—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000914	0.00155	CcSEcCtD
Triazolam—Jaundice—Doxorubicin—urinary bladder cancer	0.000904	0.00153	CcSEcCtD
Triazolam—Stomatitis—Doxorubicin—urinary bladder cancer	0.000904	0.00153	CcSEcCtD
Triazolam—Abdominal pain—Etoposide—urinary bladder cancer	0.000902	0.00152	CcSEcCtD
Triazolam—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000899	0.00152	CcSEcCtD
Triazolam—Tinnitus—Methotrexate—urinary bladder cancer	0.000897	0.00152	CcSEcCtD
Triazolam—Asthenia—Cisplatin—urinary bladder cancer	0.000893	0.00151	CcSEcCtD
Triazolam—Dizziness—Fluorouracil—urinary bladder cancer	0.000869	0.00147	CcSEcCtD
Triazolam—Visual impairment—Epirubicin—urinary bladder cancer	0.000867	0.00147	CcSEcCtD
Triazolam—Diarrhoea—Cisplatin—urinary bladder cancer	0.000852	0.00144	CcSEcCtD
Triazolam—Vomiting—Gemcitabine—urinary bladder cancer	0.000849	0.00144	CcSEcCtD
Triazolam—Dermatitis—Gemcitabine—urinary bladder cancer	0.000842	0.00142	CcSEcCtD
Triazolam—Hypersensitivity—Etoposide—urinary bladder cancer	0.00084	0.00142	CcSEcCtD
Triazolam—Tinnitus—Epirubicin—urinary bladder cancer	0.000839	0.00142	CcSEcCtD
Triazolam—Erythema—Methotrexate—urinary bladder cancer	0.000837	0.00142	CcSEcCtD
Triazolam—Headache—Gemcitabine—urinary bladder cancer	0.000837	0.00141	CcSEcCtD
Triazolam—Vomiting—Fluorouracil—urinary bladder cancer	0.000835	0.00141	CcSEcCtD
Triazolam—Dermatitis—Fluorouracil—urinary bladder cancer	0.000827	0.0014	CcSEcCtD
Triazolam—Headache—Fluorouracil—urinary bladder cancer	0.000823	0.00139	CcSEcCtD
Triazolam—Dysgeusia—Methotrexate—urinary bladder cancer	0.00082	0.00139	CcSEcCtD
Triazolam—Asthenia—Etoposide—urinary bladder cancer	0.000818	0.00138	CcSEcCtD
Triazolam—Pruritus—Etoposide—urinary bladder cancer	0.000807	0.00136	CcSEcCtD
Triazolam—Visual impairment—Doxorubicin—urinary bladder cancer	0.000803	0.00136	CcSEcCtD
Triazolam—Nausea—Gemcitabine—urinary bladder cancer	0.000794	0.00134	CcSEcCtD
Triazolam—Vomiting—Cisplatin—urinary bladder cancer	0.000792	0.00134	CcSEcCtD
Triazolam—Dermatitis—Cisplatin—urinary bladder cancer	0.000784	0.00133	CcSEcCtD
Triazolam—Erythema—Epirubicin—urinary bladder cancer	0.000784	0.00132	CcSEcCtD
Triazolam—Diarrhoea—Etoposide—urinary bladder cancer	0.000781	0.00132	CcSEcCtD
Triazolam—Nausea—Fluorouracil—urinary bladder cancer	0.00078	0.00132	CcSEcCtD
Triazolam—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000777	0.00131	CcSEcCtD
Triazolam—Tinnitus—Doxorubicin—urinary bladder cancer	0.000776	0.00131	CcSEcCtD
Triazolam—Flatulence—Epirubicin—urinary bladder cancer	0.000772	0.00131	CcSEcCtD
Triazolam—Tension—Epirubicin—urinary bladder cancer	0.000769	0.0013	CcSEcCtD
Triazolam—Dysgeusia—Epirubicin—urinary bladder cancer	0.000767	0.0013	CcSEcCtD
Triazolam—Nervousness—Epirubicin—urinary bladder cancer	0.000761	0.00129	CcSEcCtD
Triazolam—Malaise—Methotrexate—urinary bladder cancer	0.000755	0.00128	CcSEcCtD
Triazolam—Dizziness—Etoposide—urinary bladder cancer	0.000754	0.00128	CcSEcCtD
Triazolam—Muscle spasms—Epirubicin—urinary bladder cancer	0.000753	0.00127	CcSEcCtD
Triazolam—Nausea—Cisplatin—urinary bladder cancer	0.00074	0.00125	CcSEcCtD
Triazolam—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000727	0.00123	CcSEcCtD
Triazolam—Vomiting—Etoposide—urinary bladder cancer	0.000725	0.00123	CcSEcCtD
Triazolam—Erythema—Doxorubicin—urinary bladder cancer	0.000725	0.00123	CcSEcCtD
Triazolam—Agitation—Epirubicin—urinary bladder cancer	0.00072	0.00122	CcSEcCtD
Triazolam—Dermatitis—Etoposide—urinary bladder cancer	0.000719	0.00121	CcSEcCtD
Triazolam—Headache—Etoposide—urinary bladder cancer	0.000715	0.00121	CcSEcCtD
Triazolam—Flatulence—Doxorubicin—urinary bladder cancer	0.000714	0.00121	CcSEcCtD
Triazolam—Chest pain—Methotrexate—urinary bladder cancer	0.000713	0.00121	CcSEcCtD
Triazolam—Tension—Doxorubicin—urinary bladder cancer	0.000711	0.0012	CcSEcCtD
Triazolam—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00071	0.0012	CcSEcCtD
Triazolam—Malaise—Epirubicin—urinary bladder cancer	0.000707	0.00119	CcSEcCtD
Triazolam—Discomfort—Methotrexate—urinary bladder cancer	0.000704	0.00119	CcSEcCtD
Triazolam—Nervousness—Doxorubicin—urinary bladder cancer	0.000704	0.00119	CcSEcCtD
Triazolam—Syncope—Epirubicin—urinary bladder cancer	0.000703	0.00119	CcSEcCtD
Triazolam—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000697	0.00118	CcSEcCtD
Triazolam—Palpitations—Epirubicin—urinary bladder cancer	0.000692	0.00117	CcSEcCtD
Triazolam—Confusional state—Methotrexate—urinary bladder cancer	0.000689	0.00116	CcSEcCtD
Triazolam—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000689	0.00116	CcSEcCtD
Triazolam—Nausea—Etoposide—urinary bladder cancer	0.000678	0.00115	CcSEcCtD
Triazolam—Hypertension—Epirubicin—urinary bladder cancer	0.000676	0.00114	CcSEcCtD
Triazolam—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000673	0.00114	CcSEcCtD
Triazolam—Chest pain—Epirubicin—urinary bladder cancer	0.000667	0.00113	CcSEcCtD
Triazolam—Agitation—Doxorubicin—urinary bladder cancer	0.000666	0.00113	CcSEcCtD
Triazolam—Anxiety—Epirubicin—urinary bladder cancer	0.000665	0.00112	CcSEcCtD
Triazolam—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000661	0.00112	CcSEcCtD
Triazolam—Discomfort—Epirubicin—urinary bladder cancer	0.000659	0.00111	CcSEcCtD
Triazolam—Malaise—Doxorubicin—urinary bladder cancer	0.000654	0.00111	CcSEcCtD
Triazolam—Dry mouth—Epirubicin—urinary bladder cancer	0.000652	0.0011	CcSEcCtD
Triazolam—Anorexia—Methotrexate—urinary bladder cancer	0.000651	0.0011	CcSEcCtD
Triazolam—Syncope—Doxorubicin—urinary bladder cancer	0.00065	0.0011	CcSEcCtD
Triazolam—Confusional state—Epirubicin—urinary bladder cancer	0.000645	0.00109	CcSEcCtD
Triazolam—Palpitations—Doxorubicin—urinary bladder cancer	0.000641	0.00108	CcSEcCtD
Triazolam—Oedema—Epirubicin—urinary bladder cancer	0.000639	0.00108	CcSEcCtD
Triazolam—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000637	0.00108	CcSEcCtD
Triazolam—Shock—Epirubicin—urinary bladder cancer	0.000629	0.00106	CcSEcCtD
Triazolam—Hypertension—Doxorubicin—urinary bladder cancer	0.000626	0.00106	CcSEcCtD
Triazolam—Tachycardia—Epirubicin—urinary bladder cancer	0.000624	0.00106	CcSEcCtD
Triazolam—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000618	0.00105	CcSEcCtD
Triazolam—Insomnia—Methotrexate—urinary bladder cancer	0.000618	0.00104	CcSEcCtD
Triazolam—Chest pain—Doxorubicin—urinary bladder cancer	0.000617	0.00104	CcSEcCtD
Triazolam—Anxiety—Doxorubicin—urinary bladder cancer	0.000615	0.00104	CcSEcCtD
Triazolam—Paraesthesia—Methotrexate—urinary bladder cancer	0.000614	0.00104	CcSEcCtD
Triazolam—Discomfort—Doxorubicin—urinary bladder cancer	0.00061	0.00103	CcSEcCtD
Triazolam—Anorexia—Epirubicin—urinary bladder cancer	0.00061	0.00103	CcSEcCtD
Triazolam—Dyspnoea—Methotrexate—urinary bladder cancer	0.000609	0.00103	CcSEcCtD
Triazolam—Somnolence—Methotrexate—urinary bladder cancer	0.000607	0.00103	CcSEcCtD
Triazolam—Dry mouth—Doxorubicin—urinary bladder cancer	0.000604	0.00102	CcSEcCtD
Triazolam—Confusional state—Doxorubicin—urinary bladder cancer	0.000597	0.00101	CcSEcCtD
Triazolam—Decreased appetite—Methotrexate—urinary bladder cancer	0.000594	0.001	CcSEcCtD
Triazolam—Oedema—Doxorubicin—urinary bladder cancer	0.000592	0.001	CcSEcCtD
Triazolam—Fatigue—Methotrexate—urinary bladder cancer	0.000589	0.000996	CcSEcCtD
Triazolam—Pain—Methotrexate—urinary bladder cancer	0.000584	0.000988	CcSEcCtD
Triazolam—Shock—Doxorubicin—urinary bladder cancer	0.000582	0.000984	CcSEcCtD
Triazolam—Insomnia—Epirubicin—urinary bladder cancer	0.000578	0.000978	CcSEcCtD
Triazolam—Tachycardia—Doxorubicin—urinary bladder cancer	0.000577	0.000976	CcSEcCtD
Triazolam—Paraesthesia—Epirubicin—urinary bladder cancer	0.000574	0.000971	CcSEcCtD
Triazolam—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000572	0.000967	CcSEcCtD
Triazolam—Dyspnoea—Epirubicin—urinary bladder cancer	0.00057	0.000964	CcSEcCtD
Triazolam—Somnolence—Epirubicin—urinary bladder cancer	0.000568	0.000961	CcSEcCtD
Triazolam—Anorexia—Doxorubicin—urinary bladder cancer	0.000564	0.000953	CcSEcCtD
Triazolam—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000563	0.000952	CcSEcCtD
Triazolam—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000559	0.000945	CcSEcCtD
Triazolam—Decreased appetite—Epirubicin—urinary bladder cancer	0.000556	0.00094	CcSEcCtD
Triazolam—Fatigue—Epirubicin—urinary bladder cancer	0.000551	0.000932	CcSEcCtD
Triazolam—Pain—Epirubicin—urinary bladder cancer	0.000547	0.000924	CcSEcCtD
Triazolam—Constipation—Epirubicin—urinary bladder cancer	0.000547	0.000924	CcSEcCtD
Triazolam—Abdominal pain—Methotrexate—urinary bladder cancer	0.00054	0.000913	CcSEcCtD
Triazolam—Insomnia—Doxorubicin—urinary bladder cancer	0.000535	0.000905	CcSEcCtD
Triazolam—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000531	0.000898	CcSEcCtD
Triazolam—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000527	0.000892	CcSEcCtD
Triazolam—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000527	0.000891	CcSEcCtD
Triazolam—Somnolence—Doxorubicin—urinary bladder cancer	0.000526	0.000889	CcSEcCtD
Triazolam—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000523	0.000884	CcSEcCtD
Triazolam—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000514	0.00087	CcSEcCtD
Triazolam—Fatigue—Doxorubicin—urinary bladder cancer	0.00051	0.000862	CcSEcCtD
Triazolam—Pain—Doxorubicin—urinary bladder cancer	0.000506	0.000855	CcSEcCtD
Triazolam—Constipation—Doxorubicin—urinary bladder cancer	0.000506	0.000855	CcSEcCtD
Triazolam—Abdominal pain—Epirubicin—urinary bladder cancer	0.000505	0.000855	CcSEcCtD
Triazolam—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000503	0.000851	CcSEcCtD
Triazolam—Asthenia—Methotrexate—urinary bladder cancer	0.00049	0.000829	CcSEcCtD
Triazolam—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000488	0.000824	CcSEcCtD
Triazolam—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000484	0.000818	CcSEcCtD
Triazolam—Pruritus—Methotrexate—urinary bladder cancer	0.000483	0.000817	CcSEcCtD
Triazolam—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000471	0.000796	CcSEcCtD
Triazolam—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000468	0.000791	CcSEcCtD
Triazolam—Diarrhoea—Methotrexate—urinary bladder cancer	0.000468	0.00079	CcSEcCtD
Triazolam—Asthenia—Epirubicin—urinary bladder cancer	0.000459	0.000776	CcSEcCtD
Triazolam—Pruritus—Epirubicin—urinary bladder cancer	0.000452	0.000765	CcSEcCtD
Triazolam—Dizziness—Methotrexate—urinary bladder cancer	0.000452	0.000764	CcSEcCtD
Triazolam—Diarrhoea—Epirubicin—urinary bladder cancer	0.000438	0.00074	CcSEcCtD
Triazolam—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000436	0.000737	CcSEcCtD
Triazolam—Vomiting—Methotrexate—urinary bladder cancer	0.000434	0.000734	CcSEcCtD
Triazolam—Dermatitis—Methotrexate—urinary bladder cancer	0.00043	0.000728	CcSEcCtD
Triazolam—Headache—Methotrexate—urinary bladder cancer	0.000428	0.000724	CcSEcCtD
Triazolam—Asthenia—Doxorubicin—urinary bladder cancer	0.000425	0.000718	CcSEcCtD
Triazolam—Dizziness—Epirubicin—urinary bladder cancer	0.000423	0.000715	CcSEcCtD
Triazolam—Pruritus—Doxorubicin—urinary bladder cancer	0.000419	0.000708	CcSEcCtD
Triazolam—Vomiting—Epirubicin—urinary bladder cancer	0.000407	0.000687	CcSEcCtD
Triazolam—Nausea—Methotrexate—urinary bladder cancer	0.000406	0.000686	CcSEcCtD
Triazolam—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000405	0.000684	CcSEcCtD
Triazolam—Dermatitis—Epirubicin—urinary bladder cancer	0.000403	0.000681	CcSEcCtD
Triazolam—Headache—Epirubicin—urinary bladder cancer	0.000401	0.000677	CcSEcCtD
Triazolam—Dizziness—Doxorubicin—urinary bladder cancer	0.000391	0.000661	CcSEcCtD
Triazolam—Nausea—Epirubicin—urinary bladder cancer	0.00038	0.000642	CcSEcCtD
Triazolam—Vomiting—Doxorubicin—urinary bladder cancer	0.000376	0.000636	CcSEcCtD
Triazolam—Dermatitis—Doxorubicin—urinary bladder cancer	0.000373	0.00063	CcSEcCtD
Triazolam—Headache—Doxorubicin—urinary bladder cancer	0.000371	0.000627	CcSEcCtD
Triazolam—Nausea—Doxorubicin—urinary bladder cancer	0.000351	0.000594	CcSEcCtD
Triazolam—GABRG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00017	0.00171	CbGpPWpGaD
Triazolam—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00017	0.00171	CbGpPWpGaD
Triazolam—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000169	0.0017	CbGpPWpGaD
Triazolam—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000163	0.00164	CbGpPWpGaD
Triazolam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000152	0.00152	CbGpPWpGaD
Triazolam—GABRG3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000149	0.0015	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000149	0.0015	CbGpPWpGaD
Triazolam—GABRB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000147	0.00148	CbGpPWpGaD
Triazolam—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000142	0.00143	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000139	0.0014	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000139	0.0014	CbGpPWpGaD
Triazolam—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000138	0.00138	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000137	0.00138	CbGpPWpGaD
Triazolam—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000135	0.00136	CbGpPWpGaD
Triazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	0.000134	0.00135	CbGpPWpGaD
Triazolam—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000133	0.00134	CbGpPWpGaD
Triazolam—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000133	0.00134	CbGpPWpGaD
Triazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	0.000128	0.00129	CbGpPWpGaD
Triazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	0.000128	0.00129	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000126	0.00127	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000126	0.00126	CbGpPWpGaD
Triazolam—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000124	0.00125	CbGpPWpGaD
Triazolam—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000123	0.00123	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000122	0.00123	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00012	0.00121	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000118	0.00119	CbGpPWpGaD
Triazolam—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000117	0.00118	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000117	0.00118	CbGpPWpGaD
Triazolam—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000117	0.00118	CbGpPWpGaD
Triazolam—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000116	0.00116	CbGpPWpGaD
Triazolam—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000115	0.00116	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000115	0.00116	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	0.000115	0.00115	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—SRC—urinary bladder cancer	0.000115	0.00115	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000111	0.00111	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—NAT1—urinary bladder cancer	0.000109	0.00109	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	0.000109	0.00109	CbGpPWpGaD
Triazolam—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000108	0.00108	CbGpPWpGaD
Triazolam—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000106	0.00107	CbGpPWpGaD
Triazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	0.000105	0.00106	CbGpPWpGaD
Triazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	0.000104	0.00104	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000102	0.00103	CbGpPWpGaD
Triazolam—GABRR1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000101	0.00101	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.0001	0.00101	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	9.94e-05	0.001	CbGpPWpGaD
Triazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	9.8e-05	0.000987	CbGpPWpGaD
Triazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	9.68e-05	0.000974	CbGpPWpGaD
Triazolam—GABRQ—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	9.6e-05	0.000966	CbGpPWpGaD
Triazolam—GABRR2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	9.6e-05	0.000966	CbGpPWpGaD
Triazolam—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	9.54e-05	0.00096	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	9.48e-05	0.000954	CbGpPWpGaD
Triazolam—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.41e-05	0.000947	CbGpPWpGaD
Triazolam—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	9.35e-05	0.000942	CbGpPWpGaD
Triazolam—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	9.07e-05	0.000913	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	8.95e-05	0.000901	CbGpPWpGaD
Triazolam—GABRR1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.89e-05	0.000895	CbGpPWpGaD
Triazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.85e-05	0.000891	CbGpPWpGaD
Triazolam—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	8.76e-05	0.000882	CbGpPWpGaD
Triazolam—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.64e-05	0.00087	CbGpPWpGaD
Triazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.6e-05	0.000866	CbGpPWpGaD
Triazolam—GABRQ—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.48e-05	0.000854	CbGpPWpGaD
Triazolam—GABRR2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.48e-05	0.000854	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	8.45e-05	0.000851	CbGpPWpGaD
Triazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.44e-05	0.00085	CbGpPWpGaD
Triazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.3e-05	0.000835	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	8.29e-05	0.000834	CbGpPWpGaD
Triazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.24e-05	0.00083	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	8.24e-05	0.000829	CbGpPWpGaD
Triazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	8.1e-05	0.000815	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—HRAS—urinary bladder cancer	8.06e-05	0.000811	CbGpPWpGaD
Triazolam—GABRG3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.91e-05	0.000796	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	7.86e-05	0.000791	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—NAT1—urinary bladder cancer	7.86e-05	0.000791	CbGpPWpGaD
Triazolam—GABRB1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.79e-05	0.000784	CbGpPWpGaD
Triazolam—GABRR1—Neuronal System—HRAS—urinary bladder cancer	7.71e-05	0.000776	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	7.7e-05	0.000775	CbGpPWpGaD
Triazolam—GABRA6—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.37e-05	0.000742	CbGpPWpGaD
Triazolam—GABRR2—Neuronal System—HRAS—urinary bladder cancer	7.36e-05	0.00074	CbGpPWpGaD
Triazolam—GABRQ—Neuronal System—HRAS—urinary bladder cancer	7.36e-05	0.00074	CbGpPWpGaD
Triazolam—GABRA4—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.28e-05	0.000732	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	7.19e-05	0.000723	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	7.18e-05	0.000722	CbGpPWpGaD
Triazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	7.08e-05	0.000712	CbGpPWpGaD
Triazolam—GABRG3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.99e-05	0.000703	CbGpPWpGaD
Triazolam—GABRB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.88e-05	0.000693	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	6.8e-05	0.000685	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—NAT1—urinary bladder cancer	6.8e-05	0.000685	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.69e-05	0.000674	CbGpPWpGaD
Triazolam—GABRB2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.65e-05	0.00067	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—TYMP—urinary bladder cancer	6.58e-05	0.000663	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.51e-05	0.000655	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	6.47e-05	0.000651	CbGpPWpGaD
Triazolam—GABRA5—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.46e-05	0.000651	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.43e-05	0.000647	CbGpPWpGaD
Triazolam—GABRA3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.35e-05	0.000639	CbGpPWpGaD
Triazolam—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.29e-05	0.000633	CbGpPWpGaD
Triazolam—GABRA2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.24e-05	0.000628	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	6.22e-05	0.000626	CbGpPWpGaD
Triazolam—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.2e-05	0.000624	CbGpPWpGaD
Triazolam—GABRB3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.2e-05	0.000624	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	6.11e-05	0.000615	CbGpPWpGaD
Triazolam—GABRG2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.09e-05	0.000613	CbGpPWpGaD
Triazolam—GABRG3—Neuronal System—HRAS—urinary bladder cancer	6.06e-05	0.00061	CbGpPWpGaD
Triazolam—GABRB1—Neuronal System—HRAS—urinary bladder cancer	5.97e-05	0.000601	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—NAT2—urinary bladder cancer	5.95e-05	0.000599	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	5.95e-05	0.000599	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.88e-05	0.000592	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.84e-05	0.000588	CbGpPWpGaD
Triazolam—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.78e-05	0.000582	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.71e-05	0.000575	CbGpPWpGaD
Triazolam—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.7e-05	0.000574	CbGpPWpGaD
Triazolam—GABRA6—Neuronal System—HRAS—urinary bladder cancer	5.65e-05	0.000568	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.61e-05	0.000565	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	5.6e-05	0.000564	CbGpPWpGaD
Triazolam—GABRA4—Neuronal System—HRAS—urinary bladder cancer	5.57e-05	0.000561	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.54e-05	0.000557	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.54e-05	0.000557	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.51e-05	0.000555	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.48e-05	0.000551	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.45e-05	0.000548	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.38e-05	0.000541	CbGpPWpGaD
Triazolam—GABRA1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.32e-05	0.000535	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	5.29e-05	0.000533	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	5.16e-05	0.000519	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—RRM2—urinary bladder cancer	5.14e-05	0.000517	CbGpPWpGaD
Triazolam—GABRB2—Neuronal System—HRAS—urinary bladder cancer	5.1e-05	0.000513	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.07e-05	0.00051	CbGpPWpGaD
Triazolam—GABRA5—Neuronal System—HRAS—urinary bladder cancer	4.95e-05	0.000499	CbGpPWpGaD
Triazolam—GABRA3—Neuronal System—HRAS—urinary bladder cancer	4.86e-05	0.00049	CbGpPWpGaD
Triazolam—GABRA2—Neuronal System—HRAS—urinary bladder cancer	4.78e-05	0.000481	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—ENO2—urinary bladder cancer	4.76e-05	0.000479	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	4.76e-05	0.000479	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—TYMP—urinary bladder cancer	4.76e-05	0.000479	CbGpPWpGaD
Triazolam—GABRB3—Neuronal System—HRAS—urinary bladder cancer	4.75e-05	0.000478	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.7e-05	0.000473	CbGpPWpGaD
Triazolam—GABRG2—Neuronal System—HRAS—urinary bladder cancer	4.66e-05	0.000469	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	4.62e-05	0.000465	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.56e-05	0.000459	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.31e-05	0.000433	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—NAT2—urinary bladder cancer	4.3e-05	0.000433	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.2e-05	0.000422	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.13e-05	0.000416	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—TYMP—urinary bladder cancer	4.12e-05	0.000415	CbGpPWpGaD
Triazolam—GABRA1—Neuronal System—HRAS—urinary bladder cancer	4.08e-05	0.00041	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.96e-05	0.000399	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.85e-05	0.000388	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—NQO1—urinary bladder cancer	3.84e-05	0.000386	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—NAT2—urinary bladder cancer	3.73e-05	0.000375	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—RRM2—urinary bladder cancer	3.72e-05	0.000374	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.65e-05	0.000368	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.65e-05	0.000368	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—ENO2—urinary bladder cancer	3.44e-05	0.000346	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	3.44e-05	0.000346	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.37e-05	0.000339	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.36e-05	0.000338	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.34e-05	0.000336	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	3.34e-05	0.000336	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.22e-05	0.000324	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—RRM2—urinary bladder cancer	3.22e-05	0.000324	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	3.2e-05	0.000322	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.03e-05	0.000305	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.01e-05	0.000303	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—ENO2—urinary bladder cancer	2.98e-05	0.0003	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	2.98e-05	0.0003	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—TYMS—urinary bladder cancer	2.98e-05	0.000299	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.96e-05	0.000298	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	2.94e-05	0.000296	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	2.94e-05	0.000296	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.89e-05	0.000291	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.85e-05	0.000287	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.84e-05	0.000286	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GPX1—urinary bladder cancer	2.82e-05	0.000283	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.77e-05	0.000279	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.77e-05	0.000279	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	2.77e-05	0.000278	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.62e-05	0.000264	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	2.6e-05	0.000262	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.43e-05	0.000244	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.43e-05	0.000244	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.41e-05	0.000243	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2.4e-05	0.000242	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.35e-05	0.000237	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.33e-05	0.000235	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.32e-05	0.000233	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.31e-05	0.000233	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.21e-05	0.000223	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.15e-05	0.000216	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.13e-05	0.000214	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.13e-05	0.000214	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.11e-05	0.000212	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.04e-05	0.000205	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.03e-05	0.000205	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.02e-05	0.000204	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2e-05	0.000202	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2e-05	0.000201	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2e-05	0.000201	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.96e-05	0.000197	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.94e-05	0.000195	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.9e-05	0.000191	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.88e-05	0.000189	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.86e-05	0.000188	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.84e-05	0.000185	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.84e-05	0.000185	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.76e-05	0.000177	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.73e-05	0.000174	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.73e-05	0.000174	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.66e-05	0.000167	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.65e-05	0.000167	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.63e-05	0.000164	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.63e-05	0.000164	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.6e-05	0.000161	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.6e-05	0.000161	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.58e-05	0.000159	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.55e-05	0.000156	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.52e-05	0.000153	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.52e-05	0.000153	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.5e-05	0.000151	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.5e-05	0.000151	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.46e-05	0.000147	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.45e-05	0.000146	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.44e-05	0.000144	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.41e-05	0.000142	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.38e-05	0.000139	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.32e-05	0.000133	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.32e-05	0.000133	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.29e-05	0.00013	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.27e-05	0.000128	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.2e-05	0.000121	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000108	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.07e-05	0.000108	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.05e-05	0.000105	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.04e-05	0.000104	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.03e-05	0.000104	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1e-05	0.000101	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—EP300—urinary bladder cancer	9.97e-06	0.0001	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	9.88e-06	9.95e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	9.88e-06	9.95e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GPX1—urinary bladder cancer	9.46e-06	9.53e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.29e-06	9.35e-05	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PTEN—urinary bladder cancer	9.05e-06	9.11e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	8.73e-06	8.79e-05	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—EP300—urinary bladder cancer	8.63e-06	8.69e-05	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.45e-06	8.5e-05	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.37e-06	7.42e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.08e-06	7.13e-05	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.03e-06	7.07e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.8e-06	6.85e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.57e-06	5.61e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.86e-06	4.89e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.63e-06	4.66e-05	CbGpPWpGaD
